Perioperative medicine & outcomes
Cost effectiveness and long-term outcomes of dexamethasone administration in major non-cardiac surgery
Authors' conclusion
In conclusion, our study does not demonstrate the cost effectiveness of perioperative administration of DXM in major non-cardiac surgery.
Study context
- Population
- Patients undergoing major non-cardiac surgery in the PACMAN trialof 1222 randomised
- Participants
- 137 patients
- Comparison
- Dexamethasone vs placebo
- DXMn = 71
- Placebon = 66reference
- Primary endpoint
- Cost effectiveness of dexamethasone vs placebo (health payer perspective)
- Follow-up
- 12 months
Methodological detailscost-effectiveness analysis, multicentre, double-blind, placebo-controlled, health payer perspective, Followed up for 12 months after surgery
- Cost-effectiveness analysis
- Multicentre
- Double-blind
- Placebo-controlled
- Health payer perspective
- Followed up for 12 months after surgery
Primary result
As reported in the abstract
Cost per patient (health payer perspective) · 1 year
Postoperative dexamethasone reduced costs per patient at 1 year by (95%CI -€1519.99 to €803.87)
€358.06
Probability of dexamethasone being cost effective at willingness to pay €100,000 to €150,000 per life-year (France threshold)
between 12% and 22%
Probability of dexamethasone being cost effective at willingness to pay €50,000 per life-year (USA threshold)
52%
Further findings
Mortality · 12 months
Original publication
Cost effectiveness and long-term outcomes of dexamethasone administration in major non-cardiac surgery. J Clin Anesth. Published 22 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →